Kai Kupferschmidt
Abstract
Open-access reader
The pricing of pharmaceutical products in Germany is set to undergo its largest change in decades as a result of government legislation that brings free pricing to an end in a bid to contain spiralling drug costs. Currently, Germany is one of the only countries in the world, in which pharmaceutical
OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The pricing of pharmaceutical products in Germany is set to undergo its largest change in decades as a result of government legislation that brings free pricing to an end in a bid to contain spiralling drug costs. Currently, Germany is one of the only countries in the world, in which pharmaceutical
Key concepts: Legislation, Drug pricing, Drug prices, Government (linguistics), Drug industry, Business, Drug, Computer science